Qiagen has launched a digital PCR partnership program to accelerate the development of innovative assays for its QiAcuityDx clinical platform. After registering its first partner, Gencurix, Qiagen is actively cultivating a pipeline of collaborators including diagnostic developers and academic centers. The QiAcuity system, introduced in 2019, now boasts 2,700 instrument placements, with the clinical QiAcuityDx version arriving in late 2024. This open collaboration model aims to enhance assay development nimbleness, complementing Qiagen’s capabilities while broadening clinical adoption. Digital PCR provides enhanced precision over qPCR and is becoming more cost competitive.